BioNTech CEO Ugur Sahin Sells $3.3M in Ordinary Shares Under 10b5-1 Plan

Executive Summary

On October 2, 2026, BioNTech SE ($BNTX) Chief Executive Officer and 10% beneficial owner Dr. Ugur Sahin filed a Form 4 detailing open-market sales of 34,000 ordinary shares for an aggregate value of approximately $3.30 million. The sales occurred across two trading days:

• October 1, 2026: 17,000 ordinary shares sold at a weighted average price of $97.4556 ($1,656,745.20)
• October 2, 2026: 17,000 ordinary shares sold at a weighted average price of $96.7249 ($1,644,323.30)

Transaction Context & Plan Details

• 10b5-1 Trading Plan: The sales were conducted pursuant to a pre-scheduled Rule 10b5-1 trading plan adopted by Dr. Sahin on June 3, 2026, satisfying the required cooling-off period under SEC regulations.
• Direct vs. Indirect Holdings: Following the completion of these sales, Dr. Sahin directly owns 180,209 ordinary shares. In addition, he retains indirect beneficial ownership of 39,218,111 ordinary shares held through Medine GmbH, of which he is the sole shareholder.

Significance Assessment

While the gross sale proceeds exceed $3.3 million, the transaction represents a negligible fraction (less than 0.1%) of Dr. Sahin's total combined beneficial ownership of over 39.3 million shares. Because the transaction was executed under an established Rule 10b5-1 plan, it reflects routine portfolio diversification rather than a discretionary market-timing decision.